Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025

尿道カテーテルの世界市場予測(〜2025):製品別(留置、断続的、外部)、種類別(コーティング、非コーティング)、用途別(尿失禁、良性前立腺肥大症、一般外科)、使用別(男性、女性)、エンドユーザー別(病院)

◆タイトル:Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025
◆商品コード:MD 5544
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年9月10日
◆ページ数:160
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥519,750見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

Marketsandmarkets社は尿道カテーテルの世界市場が2020年20億ドルから2025年26億ドルまで、年平均5.5%成長すると予測しています。本調査レポートでは、尿道カテーテルの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(留置カテーテル、断続的カテーテル、外部カテーテル)分析、種類別(コーティングカテーテル、非コーティングカテーテル)分析、使用別(男性、女性)分析、用途別(尿失禁、一般外科、良性前立腺肥大症、その他)分析、エンドユーザー別(病院、介護施設)分析、地域別分析、競争状況、企業評価・情報などをまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・尿道カテーテルの世界市場規模:製品別(留置カテーテル、断続的カテーテル、外部カテーテル)
・尿道カテーテルの世界市場規模:種類別(コーティングカテーテル、非コーティングカテーテル)
・尿道カテーテルの世界市場規模:使用別(男性、女性)
・尿道カテーテルの世界市場規模:用途別(尿失禁、一般外科、良性前立腺肥大症、その他)
・尿道カテーテルの世界市場規模:エンドユーザー別(病院、介護施設)
・尿道カテーテルの世界市場規模:地域別
・競争状況
・企業評価・情報

“Increasing number of surgical procedures, high incidence of prostate cancer, and the growing prevalence of urinary incontinence are expected to drive the overall growth of the urinary catheters market.”
The global urinary catheters market size is projected to reach USD 2.6 billion by 2025 from USD 2.0 billion in 2020, at a CAGR of 5.5% during the forecast period. Market growth can be largely attributed to factors such as the growing prevalence of urinary incontinence, an increasing number of surgical procedures across the globe, high incidence of prostate cancer, and the favorable reimbursement scenario. The emerging Asian countries are also expected to offer strong growth opportunities for players in the market. The untapped market opportunities in emerging markets are also expected to provide growth opportunities for players in the market. On the other hand, the complications associated with catheterization and the availability of alternative treatment options for urinary incontinence may restrict market growth to a certain extent.

“The hospital segment is expected to dominate the market during the forecast period.”
Based on end-users, the global urinary catheters market is segmented into hospitals, long-term care
facilities, and other end users. Hospitals accounted for the largest share of the urinary catheters market in 2019. The large share of this end-user segment can be attributed to the large volume of patients visiting hospitals due to the rising prevalence of ailments requiring surgical treatment and the high incidence of chronic diseases such as urinary incontinence, multiple sclerosis, and spina bifida.

“The urinary incontinence application segment will witness the highest growth in the urinary catheters market.”
Based on application, the global urinary catheters market is segmented into urinary incontinence,
general surgery, benign prostatic hyperplasia, and other applications. The urinary incontinence segment
accounted for the largest share of the urinary catheters market in 2019. This segment is also expected to witness the highest CAGR during the forecast period. The large share and high growth of this segment can primarily be attributed to the increasing incidence of urinary incontinence, the growing geriatric population, and the rising incidence of obesity.

“North America will dominate the market during the forecast period.”
Geographically, the urinary catheters market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the urinary catheters market. The large share of this region can be attributed factors such as the high prevalence of diseases, growing geriatric population, the availability of advanced interventional products (including urinary catheters), and increasing surgical procedures performed in the region are driving market growth in North America.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 36%, Tier 2: 45%, and Tier 3: 19%
• By Designation – C-level: 33%, D-level: 40%, and Others: 27%
• By Region – North America: 36%, Europe: 28%, Asia Pacific: 19%, and Rest of the World: 17%

List of Companies Profiled in the Report
• B. Braun Melsungen AG (Germany)
• Boston Scientific Corporation (US)
• Coloplast Ltd. (Denmark)
• ConvaTec Inc. (UK)
• Becton, Dickinson and Company (US)
• Cardinal Health (US)
• Teleflex Incorporated (US)
• Wellspect HealthCare (US)
• Cook Medical (US)
• Asid Bonz GmbH (Germany)
• Degania Silicone Ltd. (Israel)
• Bactiguard (Sweden)
• Medical Technologies of Georgia (US)
• ROCAMED (Monaco)
• Well Lead Medical Co., Ltd. (China)
• Go Medical Industries Pty Ltd. (Australia)
• Cure Medical, LLC
• Amsino International, Inc. (US)
• Urocare Products, Inc. (US)
• J and M Urinary Catheters LLC. (US)
• CompactCath (US)
• Hunter Urology (England)
• MANFRED SAUER GMBH (Germany)
• Ribbel International Limited (India).

Research Coverage:
This report provides a detailed picture of the global urinary catheters market. It aims at estimating the size and future growth potential of the market across different segments, such as product, type, usage, application, end user, and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total urinary catheters market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on urinary catheters offered by the top 25 players in the urinary catheters market. The report analyses the urinary catheters market by product, type, usage, application, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various urinary catheters across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the urinary catheters market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the urinary catheters market.

【レポートの目次】

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 MARKET SCOPE 23
FIGURE 1 URINARY CATHETERS MARKET 23
1.3.1 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 24
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
FIGURE 2 RESEARCH DESIGN 25
2.2 SECONDARY DATA 26
2.2.1 KEY DATA FROM SECONDARY SOURCES 26
2.3 PRIMARY DATA 27
2.3.1 KEY DATA FROM PRIMARY SOURCES 27
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 28
2.4 MARKET SIZE ESTIMATION 28
2.4.1 BOTTOM-UP APPROACH 28
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 29
2.4.2 GROWTH FORECAST 29
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 29
FIGURE 5 DATA TRIANGULATION METHODOLOGY 30
2.6 ASSUMPTIONS FOR THE STUDY 31
3 EXECUTIVE SUMMARY 32
FIGURE 6 URINARY CATHETERS MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION) 32
FIGURE 7 URINARY CATHETERS MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION) 33
FIGURE 8 URINARY CATHETERS MARKET, BY USAGE, 2020–2025 (USD MILLION) 34
FIGURE 9 URINARY CATHETERS MARKET, BY APPLICATION,
2020 VS. 2025 (USD MILLION) 34
FIGURE 10 URINARY CATHETERS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION) 35
FIGURE 11 GEOGRAPHIC SNAPSHOT OF THE GLOBAL URINARY CATHETERS MARKET 36

4 PREMIUM INSIGHTS 37
4.1 URINARY CATHETERS MARKET OVERVIEW 37
FIGURE 12 GROWING TARGET PATIENT POPULATION TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 37
4.2 ASIA PACIFIC: URINARY CATHETERS MARKET, BY APPLICATION & COUNTRY (2019) 38
FIGURE 13 URINARY INCONTINENCE APPLICATIONS DOMINATED THE URINARY CATHETERS MARKET IN ASIA PACIFIC IN 2019 38
4.3 URINARY CATHETERS MARKET, BY END USER, 2019 39
FIGURE 14 HOSPITALS TO BE THE LARGEST END USERS OF URINARY CATHETERS DURING THE FORECAST PERIOD 39
4.4 URINARY CATHETERS MARKET: GEOGRAPHIC SNAPSHOT 39
FIGURE 15 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 39
5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
FIGURE 16 URINARY CATHETERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND TRENDS 40
5.2.1 DRIVERS 41
5.2.1.1 Growing prevalence of urinary incontinence 41
TABLE 1 GLOBAL PREVALENCE OF URINARY INCONTINENCE 41
5.2.1.1.1 Increasing rates of obesity 41
TABLE 2 PROJECTED GROWTH RATE OF OBESITY IN VARIOUS COUNTRIES 41
5.2.1.1.2 Rapidly increasing geriatric population 42
TABLE 3 GLOBAL OVERVIEW OF THE RISE IN THE AGING POPULATION (MILLION) 42
5.2.1.2 High incidence of prostate cancer 43
TABLE 4 GLOBAL INCIDENCE AND PREVALENCE OF PROSTATE CANCER 43
5.2.1.3 Increasing number of surgical procedures 43
TABLE 5 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2014 VS. 2018 44
5.2.1.4 Favorable reimbursement scenario 44
5.2.2 RESTRAINTS 45
5.2.2.1 Complications associated with catheterization and the availability of alternatives 45
5.2.3 OPPORTUNITIES 46
5.2.3.1 Emerging economies 46
5.2.4 TRENDS 46
5.2.4.1 Growing preference for single-use catheters and self-catheterization 46
5.2.5 COVID IMPACT 46
5.3 PRICING ANALYSIS 47
TABLE 6 PRICE OF URINARY CATHETERS (USD) 47
5.4 VALUE CHAIN ANALYSIS 48
FIGURE 17 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 48
5.5 SUPPLY CHAIN ANALYSIS 48
FIGURE 18 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 49
5.6 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET 50
FIGURE 19 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET 50
6 URINARY CATHETERS MARKET, BY PRODUCT 51
6.1 INTRODUCTION 52
TABLE 7 URINARY CATHETERS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 52
TABLE 8 URINARY CATHETERS MARKET, BY PRODUCT, 2018–2025 (MILLION UNITS) 52
6.2 INDWELLING CATHETERS 52
6.2.1 INDWELLING CATHETERS TO DOMINATE THE URINARY CATHETERS MARKET DURING THE FORECAST PERIOD 52
TABLE 9 INDICATIONS FOR SUPRAPUBIC AND URETHRAL CATHETERIZATION 53
TABLE 10 INDWELLING URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 54
TABLE 11 INDWELLING URINARY CATHETERS MARKET, BY REGION,
2018–2025 (MILLION UNITS) 54
6.3 INTERMITTENT CATHETERS 54
6.3.1 INTERMITTENT CATHETERS SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
TABLE 12 INTERMITTENT URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 55
TABLE 13 INTERMITTENT URINARY CATHETERS MARKET, BY REGION,
2018–2025 (MILLION UNITS) 55
6.4 EXTERNAL CATHETERS 55
6.4.1 ADVANTAGES SUCH AS MINIMIZED RISK OF DAMAGE TO THE URETHRA TO DRIVE THE MARKET FOR EXTERNAL CATHETERS 55
TABLE 14 EXTERNAL URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 56
TABLE 15 EXTERNAL URINARY CATHETERS MARKET, BY REGION,
2018–2025 (MILLION UNITS) 56
7 URINARY CATHETERS MARKET, BY TYPE 57
7.1 INTRODUCTION 58
TABLE 16 URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 58
7.2 COATED CATHETERS 58
7.2.1 COATED CATHETERS ARE THE LARGEST AND FASTEST-GROWING SEGMENT IN THE URINARY CATHETERS MARKET 58
TABLE 17 COATED URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 59
7.3 UNCOATED CATHETERS 59
7.3.1 AFFORDABLE PRICE AND EASY AVAILABILITY TO DRIVE THE MARKET FOR UNCOATED CATHETERS 59
TABLE 18 ADVANTAGES AND DISADVANTAGES OF COMMONLY USED URINARY CATHETER MATERIALS 60
TABLE 19 UNCOATED URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 61
8 URINARY CATHETERS MARKET, BY USAGE 62
8.1 INTRODUCTION 63
TABLE 20 URINARY CATHETERS MARKET, BY USAGE, 2018–2025 (USD MILLION) 63
8.2 MALE URINARY CATHETERS 63
8.2.1 HIGH INCIDENCE OF PROSTATE CANCER TO DRIVE THE MARKET FOR MALE URINARY CATHETERS 63
TABLE 21 MALE URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 63
8.3 FEMALE URINARY CATHETERS 64
8.3.1 HIGH PREVALENCE OF URINARY INCONTINENCE TO DRIVE THE MARKET FOR FEMALE URINARY CATHETERS 64
TABLE 22 FEMALE URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 64
9 URINARY CATHETERS MARKET, BY APPLICATION 65
9.1 INTRODUCTION 66
TABLE 23 URINARY CATHETERS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 66
9.2 URINARY INCONTINENCE 66
9.2.1 URINARY INCONTINENCE APPLICATION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 66
TABLE 24 URINARY CATHETERS MARKET FOR URINARY INCONTINENCE APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 67
9.3 GENERAL SURGERY 67
9.3.1 INCREASING NUMBER OF SURGERIES TO DRIVE MARKET GROWTH 67
TABLE 25 URINARY CATHETERS MARKET FOR GENERAL SURGERY APPLICATIONS,
BY REGION, 2018–2025 (USD MILLION) 67
9.4 BENIGN PROSTATIC HYPERPLASIA 68
9.4.1 GROWING GLOBAL PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA TO DRIVE THE DEMAND FOR URINARY CATHETERS 68
TABLE 26 URINARY CATHETERS MARKET FOR BENIGN PROSTATIC HYPERPLASIA APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 68
9.5 OTHER APPLICATIONS 68
TABLE 27 URINARY CATHETERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 69
10 URINARY CATHETERS MARKET, BY END USER 70
10.1 INTRODUCTION 71
TABLE 28 URINARY CATHETERS MARKET, BY END USER, 2018–2025 (USD MILLION) 71
10.2 HOSPITALS 71
10.2.1 HIGH PATIENT INFLUX AND PROCEDURAL VOLUMES MAKE HOSPITALS THE LARGEST END USERS OF URINARY CATHETERS 71
TABLE 29 URINARY CATHETERS MARKET FOR HOSPITALS, BY REGION,
2018–2025 (USD MILLION) 72
10.3 LONG-TERM CARE FACILITIES 72
10.3.1 GROWING DEMAND FOR LONG-TERM CARE SUPPORTS THE GROWTH OF THIS END-USER SEGMENT 72
TABLE 30 URINARY CATHETERS MARKET FOR LONG-TERM CARE FACILITIES,
BY REGION, 2018–2025 (USD MILLION) 72
10.4 OTHER END USERS 73
TABLE 31 URINARY CATHETERS MARKET FOR OTHER END USERS, BY REGION,
2018–2025 (USD MILLION) 73
11 URINARY CATHETERS MARKET, BY REGION 74
11.1 INTRODUCTION 75
TABLE 32 URINARY CATHETERS MARKET, BY REGION, 2018–2025 (USD MILLION) 75
11.2 NORTH AMERICA 75
FIGURE 20 NORTH AMERICA: URINARY CATHETERS MARKET SNAPSHOT 76
TABLE 33 NORTH AMERICA: URINARY CATHETERS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 77
TABLE 34 NORTH AMERICA: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 77
TABLE 35 NORTH AMERICA: URINARY CATHETERS MARKET, BY TYPE,
2018–2025 (USD MILLION) 77
TABLE 36 NORTH AMERICA: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 78
TABLE 37 NORTH AMERICA: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 78
TABLE 38 NORTH AMERICA: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 78
11.2.1 US 79
11.2.1.1 The US dominates the North American market 79
TABLE 39 US: KEY MACROINDICATORS 79
TABLE 40 US: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 80
TABLE 41 US: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 80
TABLE 42 US: URINARY CATHETERS MARKET, BY USAGE, 2018–2025 (USD MILLION) 80
TABLE 43 US: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 81
TABLE 44 US: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 81
11.2.2 CANADA 81
11.2.2.1 Rising prevalence of target diseases to positively impact the market in Canada 81
TABLE 45 CANADA: KEY MACROINDICATORS 82
TABLE 46 CANADA: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 82
TABLE 47 CANADA: URINARY CATHETERS MARKET, BY TYPE,
2018–2025 (USD MILLION) 82
TABLE 48 CANADA: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 83
TABLE 49 CANADA: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 83
TABLE 50 CANADA: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 83
11.3 EUROPE 84
TABLE 51 EUROPE: URINARY CATHETERS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 84
TABLE 52 EUROPE: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 84
TABLE 53 EUROPE: URINARY CATHETERS MARKET, BY TYPE,
2018–2025 (USD MILLION) 84
TABLE 54 EUROPE: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 85
TABLE 55 EUROPE: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 85
TABLE 56 EUROPE: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 85
11.3.1 GERMANY 86
11.3.1.1 Germany holds the largest share of the urinary catheters market in Europe 86
TABLE 57 GERMANY: KEY MACROINDICATORS 86
TABLE 58 GERMANY: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 87
TABLE 59 GERMANY: URINARY CATHETERS MARKET, BY TYPE,
2018–2025 (USD MILLION) 87
TABLE 60 GERMANY: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 87
TABLE 61 GERMANY: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 88
TABLE 62 GERMANY: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 88
11.3.2 UK 88
11.3.2.1 Large number of road accidents to drive the market for urinary catheters in the country 88
TABLE 63 UK: KEY MACROINDICATORS 89
TABLE 64 UK: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 89
TABLE 65 UK: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
TABLE 66 UK: URINARY CATHETERS MARKET, BY USAGE, 2018–2025 (USD MILLION) 89
TABLE 67 UK: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 90
TABLE 68 UK: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 90
11.3.3 FRANCE 90
11.3.3.1 Favorable government initiatives have supported market growth in France 90
TABLE 69 FRANCE: KEY MACROINDICATORS 91
TABLE 70 FRANCE: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 91
TABLE 71 FRANCE: URINARY CATHETERS MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
TABLE 72 FRANCE: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 91
TABLE 73 FRANCE: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 92
TABLE 74 FRANCE: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 92
11.3.4 ITALY 92
11.3.4.1 Increasing healthcare expenditure and investments are driving the market in Italy 92
TABLE 75 ITALY: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 93
TABLE 76 ITALY: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 77 ITALY: URINARY CATHETERS MARKET, BY USAGE, 2018–2025 (USD MILLION) 93
TABLE 78 ITALY: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 94
TABLE 79 ITALY: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 94
11.3.5 SPAIN 94
11.3.5.1 Rising geriatric population will aid the market growth 94
TABLE 80 SPAIN: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 95
TABLE 81 SPAIN: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 95
TABLE 82 SPAIN: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 95
TABLE 83 SPAIN: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 96
TABLE 84 SPAIN: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 96
11.3.6 REST OF EUROPE (ROE) 96
TABLE 85 ROE: CANCER CASES AND PROSTATE CANCER (%), BY COUNTRY, 2018 96
TABLE 86 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2006 VS. 2016 (% OF GDP) 97
TABLE 87 ROE: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 97
TABLE 88 ROE: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 89 ROE: URINARY CATHETERS MARKET, BY USAGE, 2018–2025 (USD MILLION) 98
TABLE 90 ROE: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 98
TABLE 91 ROE: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 98
11.4 ASIA PACIFIC 98
FIGURE 21 ASIA PACIFIC: URINARY CATHETERS MARKET SNAPSHOT 99
TABLE 92 APAC: URINARY CATHETERS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 99
TABLE 93 APAC: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 100
TABLE 94 APAC: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 100
TABLE 95 APAC: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 100
TABLE 96 APAC: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 101
TABLE 97 APAC: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 101
11.4.1 JAPAN 101
11.4.1.1 Japan dominates the Asia Pacific market 101
TABLE 98 JAPAN: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 102
TABLE 99 JAPAN: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 100 JAPAN: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 102
TABLE 101 JAPAN: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 103
TABLE 102 JAPAN: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 103
11.4.2 CHINA 103
11.4.2.1 Improvements in healthcare infrastructure will favor market growth in China 103
TABLE 103 CHINA: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 104
TABLE 104 CHINA: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 104
TABLE 105 CHINA: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 104
TABLE 106 CHINA: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 105
TABLE 107 CHINA: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 105
11.4.3 INDIA 105
11.4.3.1 High incidence of target medical conditions to drive the market for urinary catheters in the country 105
TABLE 108 INDIA: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 106
TABLE 109 INDIA: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 106
TABLE 110 INDIA: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 106
TABLE 111 INDIA: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 107
TABLE 112 INDIA: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 107
11.4.4 REST OF ASIA PACIFIC 107
TABLE 113 ROAPAC: CANCER CASES AND PROSTATE CANCER (%), BY COUNTRY, 2018 107
TABLE 114 ROAPAC: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 108
TABLE 115 ROAPAC: URINARY CATHETERS MARKET, BY TYPE,
2018–2025 (USD MILLION) 108
TABLE 116 ROAPAC: URINARY CATHETERS MARKET, BY USAGE,
2018–2025 (USD MILLION) 108
TABLE 117 ROAPAC: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 109
TABLE 118 ROAPAC: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 109
11.5 ROW 109
TABLE 119 ROW: NEW CANCER CASES AND PROSTATE CANCER (%), BY COUNTRY, 2018 110
TABLE 120 ROW: URINARY CATHETERS MARKET, BY REGION,
2018–2025 (USD MILLION) 110
TABLE 121 ROW: URINARY CATHETERS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 110
TABLE 122 ROW: URINARY CATHETERS MARKET, BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 123 ROW: URINARY CATHETERS MARKET, BY USAGE, 2018–2025 (USD MILLION) 111
TABLE 124 ROW: URINARY CATHETERS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 111
TABLE 125 ROW: URINARY CATHETERS MARKET, BY END USER,
2018–2025 (USD MILLION) 111
12 COMPETITIVE LANDSCAPE 112
12.1 OVERVIEW 112
FIGURE 22 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES BETWEEN 2017 AND 2020 112
FIGURE 23 MARKET EVOLUTION FRAMEWORK 113
12.2 COMPETITIVE SITUATIONS AND TRENDS 113
12.2.1 PARTNERSHIPS & AGREEMENTS 113
12.2.2 PRODUCT LAUNCHES & APPROVALS 114
12.2.3 EXPANSIONS 114
12.2.4 ACQUISITIONS 115
13 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 116
13.1 COMPANY EVALUATION MATRIX DEFINITIONS AND METHODOLOGY 116
13.1.1 MARKET SHARE ANALYSIS, 2019 116
FIGURE 24 URINARY CATHETERS MARKET, BY KEY PLAYER, 2019 116
13.2 COMPANY EVALUATION MATRIX 118
13.2.1 STARS 118
13.2.2 EMERGING LEADERS 118
13.2.3 PERVASIVE PLAYERS 118
13.2.4 PARTICIPANTS 118
FIGURE 25 MNM VENDOR DIVE COMPARISON MATRIX: URINARY CATHETERS MARKET 119

13.3 COMPETITIVE LEADERSHIP MAPPING (START-UPS) 119
13.3.1 PROGRESSIVE COMPANIES 119
13.3.2 STARTING BLOCKS 119
13.3.3 RESPONSIVE COMPANIES 120
13.3.4 DYNAMIC COMPANIES 120
FIGURE 26 MNM VENDOR DIVE COMPARISON MATRIX FOR START-UPS: URINARY CATHETERS MARKET 120
13.4 COMPANY PROFILES 121
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.4.1 COLOPLAST A/S 121
FIGURE 27 COLOPLAST A/S: COMPANY SNAPSHOT 121
13.4.2 BECTON, DICKINSON AND COMPANY (BD) 124
FIGURE 28 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 124
13.4.3 CONVATEC GROUP PLC 126
FIGURE 29 CONVATEC GROUP PLC: COMPANY SNAPSHOT 126
13.4.4 CARDINAL HEALTH 129
FIGURE 30 CARDINAL HEALTH: COMPANY SNAPSHOT 129
13.4.5 B. BRAUN MELSUNGEN AG 131
FIGURE 31 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT 131
13.4.6 BOSTON SCIENTIFIC CORPORATION 134
FIGURE 32 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 134
13.4.7 ASID BONZ GMBH 136
13.4.8 BACTIGUARD 137
FIGURE 33 BACTIGUARD: COMPANY SNAPSHOT 137
13.4.9 COOK MEDICAL 141
13.4.10 CURE MEDICAL 143
13.4.11 GO MEDICAL INDUSTRIES PTY LTD. 145
13.4.12 HOLLISTER INCORPORATED 146
13.4.13 TELEFLEX INCORPORATED 148
FIGURE 34 TELEFLEX INCORPORATED: COMPANY SNAPSHOT 148
13.4.14 WELLSPECT HEALTHCARE (A SUBSIDIARY OF DENTSPLY SIRONA INC.) 150
FIGURE 35 DENTSPLY SIRONA: COMPANY SNAPSHOT 150
13.5 OTHER COMPANIES 152
13.5.1 AMSINO INTERNATIONAL, INC. 152
13.5.2 COMPACTCATH 152
13.5.3 DEGANIA SILICONE LTD. (A PART OF Q LIFE SCIENCES) 153
13.5.4 HUNTER UROLOGY 153
13.5.5 J AND M URINARY CATHETERS LLC 154
13.5.6 MANFRED SAUER GMBH 154
13.5.7 MEDICAL TECHNOLOGIES OF GEORGIA 155
13.5.8 RIBBEL INTERNATIONAL LIMITED 156
13.5.9 ROCAMED 156
13.5.10 UROCARE PRODUCTS, INC. 157
13.5.11 WELL LEAD MEDICAL CO., LTD. 157
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 158
14.1 DISCUSSION GUIDE 158
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 162
14.3 AVAILABLE CUSTOMIZATIONS 164
14.4 RELATED REPORTS 164
14.5 AUTHOR DETAILS 165

10.3.4 SPAIN 164
10.3.4.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth 164
TABLE 127 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 165
TABLE 128 SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 165
TABLE 129 SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 165
TABLE 130 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 166
TABLE 131 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 166
10.3.5 UK 166
10.3.5.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK 166
TABLE 132 ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS IN
THE UK, 2012–2018 167
TABLE 133 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 167
TABLE 134 UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 168
TABLE 135 UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 168
TABLE 136 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 168
TABLE 137 UK: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 169
10.3.6 REST OF EUROPE 169
TABLE 138 ROE: NUMBER OF HEMOPHILIA PATIENTS, BY COUNTRY, 2012–2018 169
TABLE 139 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 170
TABLE 140 ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 170
TABLE 141 ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 171
TABLE 142 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 171
TABLE 143 ROE: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 171
10.4 ASIA PACIFIC 172
FIGURE 23 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT 173
TABLE 144 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 174
TABLE 145 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 174
TABLE 146 ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 174
TABLE 147 ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 175
TABLE 148 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 175
TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,
2019–2025 (USD MILLION) 175

10.4.1 CHINA 176
10.4.1.1 Rising incidence of diseases such as liver cancer and hepatitis B to drive market growth in China 176
TABLE 150 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 177
TABLE 151 CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 177
TABLE 152 CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 177
TABLE 153 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 178
TABLE 154 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 178
10.4.2 JAPAN 178
10.4.2.1 Rising prevalence of neurological disorders and hematological diseases will support market growth in the country 178
TABLE 155 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN,
2014 VS.2018 (IN IU/TOTAL POPULATION) 179
TABLE 156 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2018 179
TABLE 157 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 180
TABLE 158 JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 180
TABLE 159 JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 180
TABLE 160 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 181
TABLE 161 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 181
10.4.3 AUSTRALIA 181
10.4.3.1 Growing demand for plasma products for the treatment of chronic disease to drive market growth 181
TABLE 162 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2008/09–2017/18 182
TABLE 163 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2018 (USD MILLION) 182
FIGURE 24 FRESH BLOOD EXPENDITURE IN AUSTRALIA, 2008–2018 (USD MILLION) 183
TABLE 164 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017) 183
TABLE 165 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 183
TABLE 166 AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 184
TABLE 167 AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 184
TABLE 168 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 184
TABLE 169 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 185

10.4.4 INDIA 185
10.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth 185
TABLE 170 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2018 185
TABLE 171 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 186
TABLE 172 INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 186
TABLE 173 INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 187
TABLE 174 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 187
TABLE 175 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 187
10.4.5 VIETNAM 188
10.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth 188
FIGURE 25 MEAN PER CAPITA USE OF FACTOR VIII AND IX IN VIETNAM,
2014–2018 (IU/POPULATION) 188
FIGURE 26 PATIENT POPULATION SUFFERING FROM BLEEDING DISORDERS IN VIETNAM, 2014–2018 189
TABLE 176 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 189
TABLE 177 VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 189
TABLE 178 VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 190
TABLE 179 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 190
TABLE 180 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 190
10.4.6 INDONESIA 191
10.4.6.1 Growing government initiatives to drive market growth 191
TABLE 181 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 191
TABLE 182 INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 192
TABLE 183 INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 192
TABLE 184 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 192
TABLE 185 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 193
10.4.7 MALAYSIA 193
10.4.7.1 Increasing prevalence of bleeding disorders will support the plasma fractionation market in Malaysia 193
TABLE 186 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 193
TABLE 187 MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 194
TABLE 188 MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 194
TABLE 189 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 194
TABLE 190 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 195
10.4.8 REST OF ASIA PACIFIC 195
TABLE 191 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 195
TABLE 192 REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 196
TABLE 193 REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 196
TABLE 194 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 196
TABLE 195 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2018–2025 (USD MILLION) 197
10.5 LATIN AMERICA 197
10.5.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES WILL DRIVE MARKET GROWTH IN LATIN AMERICA 197
TABLE 196 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 198
TABLE 197 LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 198
TABLE 198 LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 198
TABLE 199 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 199
TABLE 200 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 199
10.6 MIDDLE EAST & AFRICA 199
TABLE 201 HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, BY COUNTRY, 2012–2018 200
TABLE 202 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2018 200
TABLE 203 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 201
TABLE 204 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 201
TABLE 205 MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 201
TABLE 206 MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 202
TABLE 207 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 202
TABLE 208 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2018–2025 (USD MILLION) 202
10.6.1 TURKEY 203
10.6.1.1 Turkey dominates the plasma fractionation market in the Middle East and Africa 203
TABLE 209 TURKEY: DEMOGRAPHIC INDICATORS 203
TABLE 210 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 203
TABLE 211 TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 204
TABLE 212 TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 204
TABLE 213 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 204
TABLE 214 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 205
10.6.2 SAUDI ARABIA 205
10.6.2.1 Developments in healthcare infrastructure to support market growth 205
TABLE 215 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 206
TABLE 216 SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE,
2018–2025 (USD MILLION) 206
TABLE 217 SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2018–2025 (USD MILLION) 206
TABLE 218 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 207
TABLE 219 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 207
10.6.3 EGYPT 207
10.6.3.1 Growing research on plasma and plasma derivatives will support market growth 207
TABLE 220 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 208
TABLE 221 EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 208
TABLE 222 EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 209
TABLE 223 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 209
TABLE 224 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 209
10.6.4 UAE 210
10.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market growth in the UAE 210
TABLE 225 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 210
TABLE 226 UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 210
TABLE 227 UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 211
TABLE 228 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 211
TABLE 229 UAE: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 211
10.6.5 REST OF THE MIDDLE EAST AND AFRICA 212
TABLE 230 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA, 2012−2018 212
TABLE 231 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 212
TABLE 232 ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2018–2025 (USD MILLION) 213
TABLE 233 ROMEA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2018–2025 (USD MILLION) 213
TABLE 234 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 213
TABLE 235 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER,
2018–2025 (USD MILLION) 214
11 COMPETITIVE LANDSCAPE 215
11.1 OVERVIEW 215
11.2 MARKET EVALUATION FRAMEWORK 215
TABLE 236 GROWTH STRATEGY MATRIX: EXPANSIONS AND COLLABORATIONS ARE
THE WIDELY ADOPTED GROWTH STRATEGIES BY MARKET PLAYERS 215
11.3 COMPETITIVE SCENARIO AND TRENDS 216
TABLE 237 PRODUCT LAUNCHES & APPROVALS, JANUARY 2017−JULY 2020 216
TABLE 238 EXPANSIONS, JANUARY 2017−JULY 2020 217
TABLE 239 ACQUISITIONS, JANUARY 2017−JULY 2020 217
TABLE 240 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, JANUARY 2017−JULY 2020 218
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 219
12.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY 219
12.1.1 MARKET SHARE ANALYSIS 219
FIGURE 27 PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019 219
12.1.2 MARKET SHARE ANALYSIS, BY PRODUCT, 2019 221
12.1.2.1 Immunoglobulins market, by key player 221
12.1.2.1.1 IVIg market, by key player 221
12.1.2.2 Coagulation factors market, by key player 222
12.1.2.2.1 Factor VIII market, by key player 222
12.1.2.3 Albumins market, by key player 223
12.1.3 MARKET SHARE ANALYSIS, BY REGION, 2019 223
12.1.3.1 North America: Plasma fractionation market, by key player 223
12.1.3.1.1 US: Plasma fractionation market, by key player 224
12.1.3.2 Europe: Plasma fractionation market, by key player 224
12.2 COMPANY EVALUATION MATRIX 225
12.2.1 STARS 225
12.2.2 EMERGING LEADERS 225
12.2.3 PERVASIVE 225
12.2.4 EMERGING COMPANIES 226
FIGURE 28 COMPETITIVE LEADERSHIP MAPPING 226
12.3 COMPANY PROFILES 227
(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
12.3.1 CSL 227
FIGURE 29 CSL: COMPANY SNAPSHOT (2019) 227
12.3.2 GRIFOLS 231
FIGURE 30 GRIFOLS: COMPANY SNAPSHOT (2019) 231
12.3.3 SHIRE 236
FIGURE 31 TAKEDA PHARMACEUTICALS: COMPANY SNAPSHOT (2019) 236
12.3.4 OCTAPHARMA 240
FIGURE 32 OCTAPHARMA: COMPANY SNAPSHOT (2019) 240
12.3.5 KEDRION 243
FIGURE 33 KEDRION: COMPANY SNAPSHOT (2019) 243
12.3.6 LFB 247
FIGURE 34 LFB: COMPANY SNAPSHOT (2016) 247
12.3.7 BIOTEST 250
FIGURE 35 BIOTEST: COMPANY SNAPSHOT (2019) 250
12.3.8 SANQUIN 253
FIGURE 36 SANQUIN: COMPANY SNAPSHOT (2018) 253
12.3.9 CHINA BIOLOGIC PRODUCTS 255
FIGURE 37 CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2019) 255
12.3.10 BIO PRODUCTS LABORATORY 258
12.3.11 JAPAN BLOOD PRODUCTS ORGANIZATION 260
FIGURE 38 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2019) 260
12.3.12 GC PHARMA 262
FIGURE 39 GC PHARMA: COMPANY SNAPSHOT (2019) 262
12.3.13 SHANGHAI RAAS BLOOD PRODUCTS 264
12.3.14 EMERGENT BIOSOLUTIONS 265
FIGURE 40 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2019) 265
12.3.15 INTAS BIOPHARMACEUTICALS 267
FIGURE 41 INTAS BIOPHARMACEUTICALS: COMPANY SNAPSHOT (2019) 267
*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies
12.3.16 OTHER COMPANIES 268
12.3.16.1 Bharat Serums and Vaccines Limited 268
12.3.16.2 SK Plasma 268
12.3.16.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. 269
12.3.16.4 Kabafusion 269
12.3.16.5 Centurion Pharma 270

13 APPENDIX 271
13.1 DISCUSSION GUIDE 271
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 275
13.3 AVAILABLE CUSTOMIZATIONS 277
13.4 RELATED REPORTS 277
13.5 AUTHOR DETAILS 278

★調査レポート[尿道カテーテルの世界市場予測(〜2025):製品別(留置、断続的、外部)、種類別(コーティング、非コーティング)、用途別(尿失禁、良性前立腺肥大症、一般外科)、使用別(男性、女性)、エンドユーザー別(病院)] ( Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025 / MD 5544) 販売に関する免責事項
[尿道カテーテルの世界市場予測(〜2025):製品別(留置、断続的、外部)、種類別(コーティング、非コーティング)、用途別(尿失禁、良性前立腺肥大症、一般外科)、使用別(男性、女性)、エンドユーザー別(病院)] ( Urinary Catheters Market by Product (Indwelling, Intermittent, External), Type (Coated, Uncoated), Application (Urinary Incontinence, Benign Prostate Hyperplasia, General Surgery), Usage (Male, Female), End Users (Hospitals) - Global Forecast to 2025 / MD 5544) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆